• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Indivior PLC

    10/24/24 4:31:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    S-8 POS 1 posteffectiveamendment.htm S-8 POS Document


    As filed with the Securities and Exchange Commission on October 24, 2024
    Registration No. 333-272596
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    Indivior PLC
    (Exact name of registrant as specified in its charter)
    England and Wales98-1204773
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    10710 Midlothian Turnpike Suite 125
    North Chesterfield, VA
    23235
    (Address of principal executive offices)(Zip Code)
    Indivior PLC Long-Term Incentive Plan
    Indivior Group Deferred Bonus Plan
    Indivior PLC U.S. Employee Stock Purchase Plan        
    Indivior Savings Related Share Option Plan
    (Full title of the plan)
    Jeff Burris, Chief Legal Officer
    Indivior PLC
    10710 Midlothian Turnpike, Suite 125
    North Chesterfield, Virginia 23255
    (Name and address of agent for service)
    (804) 379-1090
    (Telephone number, including area code, of agent for service)
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☐
    Emerging growth company☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.




    EXPLANATORY NOTE
    Indivior plc (the “Registrant”) is filing this Post-Effective Amendment No. 1 (the “Post-Effective Amendment”) to deregister any and all shares of the Registrant’s ordinary shares, $0.50 nominal value per share (the “Ordinary Shares”), registered but unissued or unsold as of the date hereof under the Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission on June 12, 2023 (File No. 333-272596) (the “Form S-8”). This Post-Effective Amendment is being filed in accordance with undertakings by the Registrant in Part II of the Form S-8 to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance but remained unsold at the termination of the offering.
    The Registrant hereby removes from registration any and all Ordinary Shares registered but unissued or unsold under the Form S-8 as of the date hereof, including 6,486,240 Ordinary Shares under the Indivior PLC Long-Term Incentive Plan, 77,821 Ordinary Shares under the Indivior Group Deferred Bonus Plan, and 454,209 Ordinary Shares under the Indivior PLC U.S. Employee Stock Purchase Plan. Except as stated above, Ordinary Shares registered on the Registration Statement are not deregistered.



    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of North Chesterfield, State of Virginia on the 2nd day of October, 2024.
                        Indivior PLC

                            By: /s/ Ryan Preblick
                             Name: Ryan Preblick
                             Title: Chief Financial Officer







    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Ryan Preblick and Jeff Burris as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to the Registration Statement, including post-effective amendments, and registration statements filed pursuant to Rule 462 under the Securities Act, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, and does hereby grant unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or any substitute therefor, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the 2nd day of October, 2024:
    NameTitle
    By:
    /s/ Mark CrossleyChief Executive Officer and Director

    Mark Crossley (Principal Executive Officer)
    By:
    /s/ Ryan PreblickChief Financial Officer and Director

    Ryan Preblick(Principal Financial Officer)
    By:
    /s/ Woodrow AndersonGroup Controller

    Woodrow Anderson(Principal Accounting Officer)
    By:
    /s/ Graham HetheringtonDirector

    Graham Hetherington
    By:
    /s/ Peter BainsDirector

    Peter Bains
    By:
    /s/ Keith HumphreysDirector

    Keith Humphreys
    By:
    /s/ Joanna Le CouilliardDirector

    Joanna Le Couilliard
    By:
    /s/ Jerome LandeDirector

    Jerome Lande
    By:
    /s/ Barbara RyanDirector

    Barbara Ryan
    By:
    /s/ Mark StejbachDirector

    Mark Stejbach
    By:
    /s/ Juliet ThompsonDirector

    Juliet Thompson
    By:
    /s/ David E. WheadonDirector

    David E. Wheadon


    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    SEC Filings

    View All

    SEC Form 15-12G filed by Indivior PLC

    15-12G - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:43 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Indivior PLC

    S-8 - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:42 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Indivior PLC

    S-8 POS - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:04:19 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A was granted 3,722 shares, increasing direct ownership by 405% to 4,642 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:11:47 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wheadon David E. was granted 5,955 shares, increasing direct ownership by 41% to 20,350 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:57 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara was granted 3,722 shares, increasing direct ownership by 190% to 5,685 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:09 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Announces Completion of Redomiciliation to the United States

    RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation ("IPI"), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol "INDV."The last day of trading Indivior PLC ordinary shares on Nasdaq was January 23, 2026. Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary sh

    1/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Provides Full-Year 2026 Financial Guidance and Business Update

    Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced its full-year 2026 financial guidance. "2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum – by growing U.S. SUBLOCADE net revenue, simplifying the organization and transform

    1/8/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Humphreys Keith bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 15% to 5,802 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:50:38 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ninivaggi Daniel A bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 5% to 16,923 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:49:33 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

    RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi

    10/16/25 4:04:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care